{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-010785","form_type":"8-K","ticker":"ADCT","cik":"0001771910","company_name":"ADC Therapeutics SA","filed_at":"2024-03-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.474767+00:00","generated_at":"2026-06-04T22:27:50.297580+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ADC Therapeutics reports Q4'23 ZYNLONTA sales $16.6M, net loss $85M; cash runway into Q4'25","bullets":["ZYNLONTA net sales $16.6M in Q4'23 (+17% QoQ, -16% YoY); FY'23 $69.1M (-8% YoY).","Net loss $85M in Q4'23 ($1.03/share) vs $23.3M loss in Q4'22; FY'23 net loss $240.1M ($2.94/share).","Cash $278.6M, expected runway into Q4'25; operating expenses decreased 21% YoY.","LOTIS-5 may need additional patients beyond 350; enrollment still expected to complete in 2024.","ADCT-601 pancreatic cancer screening initiated; LOTIS-7 dose escalation cleared at 150 µg/kg."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-010785","json":"https://secwatch.observer/filing/0001628280-24-010785.json","markdown":"https://secwatch.observer/filing/0001628280-24-010785.md","text":"https://secwatch.observer/filing/0001628280-24-010785.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1771910/000162828024010785/0001628280-24-010785-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1771910/000162828024010785/adc-20240313.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T22:27:50.297580+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f58f874b409884694ee60eb7477c2cdb9620657a","claim":"ADC Therapeutics SA reported financial results for fourth quarter and full year ended December 31, 2023.","evidence_excerpt":"On March 13, 2024, ADC Therapeutics SA (the “Company”) issued a press release and made available a corporate presentation announcing the Company’s financial results for the full year and fourth quarter ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1771910/000162828024010785/0001628280-24-010785-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}